A study of a subset of patients in the ACCESS study showed that there was a delay in making the diagnosis of sarcoidosis, even when patients presented with pulmonary symptoms. The role of the ...

Sarcoidosis is a rare systemic disease that afflicts an estimated 200,000 people in the U.S., more often people who are Black ...

The Foundation for Sarcoidosis Research (FSR) has awarded three pilot grants in the amount of $100,000 each, to Dr. Satish ...

The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

Cardiac sarcoidosis and ACM genetic variants coexist with distinct features, highlighting the need for refined clinical ...

In parallel, Xentria worked to understand the patient journey for sarcoidosis and made sure the patient’s voice was heard early in development. The biotech considered race, gender, and ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ...